Previous close | 24.20 |
Open | 24.20 |
Bid | 21.50 |
Ask | 25.50 |
Strike | 50.00 |
Expiry date | 2024-11-15 |
Day's range | 24.20 - 24.20 |
Contract range | N/A |
Volume | |
Open interest | 9 |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.